247 related articles for article (PubMed ID: 12436336)
1. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice.
Alberts P; Engblom L; Edling N; Forsgren M; Klingström G; Larsson C; Rönquist-Nii Y; Ohman B; Abrahmsén L
Diabetologia; 2002 Nov; 45(11):1528-32. PubMed ID: 12436336
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains.
Alberts P; Nilsson C; Selen G; Engblom LO; Edling NH; Norling S; Klingström G; Larsson C; Forsgren M; Ashkzari M; Nilsson CE; Fiedler M; Bergqvist E; Ohman B; Björkstrand E; Abrahmsen LB
Endocrinology; 2003 Nov; 144(11):4755-62. PubMed ID: 12960099
[TBL] [Abstract][Full Text] [Related]
3. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
[TBL] [Abstract][Full Text] [Related]
4. Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity.
Liu J; Wang L; Zhang A; Di W; Zhang X; Wu L; Yu J; Zha J; Lv S; Cheng P; Hu M; Li Y; Qi H; Ding G; Zhong Y
Endocr J; 2011; 58(3):199-209. PubMed ID: 21325744
[TBL] [Abstract][Full Text] [Related]
5. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
[TBL] [Abstract][Full Text] [Related]
6. Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Taylor A; Irwin N; McKillop AM; Flatt PR; Gault VA
Biol Chem; 2008 Apr; 389(4):441-5. PubMed ID: 18225986
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
[TBL] [Abstract][Full Text] [Related]
8. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Livingstone DE; Walker BR
J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
[TBL] [Abstract][Full Text] [Related]
9. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against the insulin resistance and hepatic steatosis in db/db mice.
Yuan X; Li H; Bai H; Zhao X; Zhang C; Liu H; Zhang Y; Zhao B; Wu Y; Liu J; Xiang Q; Feng B; Chu Y; Huang Y
Eur J Pharmacol; 2016 Oct; 788():140-151. PubMed ID: 27242185
[TBL] [Abstract][Full Text] [Related]
10. 4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice.
Zhang X; Zhou Z; Yang H; Chen J; Feng Y; Du L; Leng Y; Shen J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4455-8. PubMed ID: 19564108
[TBL] [Abstract][Full Text] [Related]
11. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds.
Blum A; Favia AD; Maser E
Mol Cell Endocrinol; 2009 Mar; 301(1-2):132-6. PubMed ID: 18822345
[TBL] [Abstract][Full Text] [Related]
12. Effect of high-fat diet on KKAy and ob/ob mouse liver and adipose tissue corticosterone and 11-dehydrocorticosterone concentrations.
Alberts P; Rönquist-Nii Y; Larsson C; Klingström G; Engblom L; Edling N; Lidell V; Berg I; Edlund PO; Ashkzari M; Sahaf N; Norling S; Berggren V; Bergdahl K; Forsgren M; Abrahmsén L
Horm Metab Res; 2005 Jul; 37(7):402-7. PubMed ID: 16034710
[TBL] [Abstract][Full Text] [Related]
13. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.
Desbriere R; Vuaroqueaux V; Achard V; Boullu-Ciocca S; Labuhn M; Dutour A; Grino M
Obesity (Silver Spring); 2006 May; 14(5):794-8. PubMed ID: 16855188
[TBL] [Abstract][Full Text] [Related]
14. BVT.2733, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice.
Wang L; Liu J; Zhang A; Cheng P; Zhang X; Lv S; Wu L; Yu J; Di W; Zha J; Kong X; Qi H; Zhong Y; Ding G
PLoS One; 2012; 7(7):e40056. PubMed ID: 22768329
[TBL] [Abstract][Full Text] [Related]
15. Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Attenuates High-Fat Diet-Induced Hepatic Steatosis in Mice.
Li H; Sheng J; Wang J; Gao H; Yu J; Ding G; Ding N; He W; Zha J
Drug Des Devel Ther; 2021; 15():2309-2324. PubMed ID: 34103895
[TBL] [Abstract][Full Text] [Related]
16. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
[TBL] [Abstract][Full Text] [Related]
17. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.
Barf T; Vallgårda J; Emond R; Häggström C; Kurz G; Nygren A; Larwood V; Mosialou E; Axelsson K; Olsson R; Engblom L; Edling N; Rönquist-Nii Y; Ohman B; Alberts P; Abrahmsén L
J Med Chem; 2002 Aug; 45(18):3813-5. PubMed ID: 12190302
[TBL] [Abstract][Full Text] [Related]
18. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Lloyd DJ; Helmering J; Cordover D; Bowsman M; Chen M; Hale C; Fordstrom P; Zhou M; Wang M; Kaufman SA; Véniant MM
Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
[TBL] [Abstract][Full Text] [Related]
19. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
Hermanowski-Vosatka A; Balkovec JM; Cheng K; Chen HY; Hernandez M; Koo GC; Le Grand CB; Li Z; Metzger JM; Mundt SS; Noonan H; Nunes CN; Olson SH; Pikounis B; Ren N; Robertson N; Schaeffer JM; Shah K; Springer MS; Strack AM; Strowski M; Wu K; Wu T; Xiao J; Zhang BB; Wright SD; Thieringer R
J Exp Med; 2005 Aug; 202(4):517-27. PubMed ID: 16103409
[TBL] [Abstract][Full Text] [Related]
20. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E
J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]